Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multinational, Randomized, Phase III Study of XELIRI With/Without Bevacizumab Versus FOLFIRI With/Without Bevacizumab As Second-line Therapy in Patients With Metastatic Colorectal Cancer
Brief Summary: The primary purpose of this study is to determine the non-inferiority of overall survival XELIRI with or without Bevacizumab compared with FOLFIRI with or without Bevacizumab as Second-line therapy in Patient with Metastatic Colorectal Cancer.


Options:
A: Arm Label: FOLFIRI +/- Bevacizumab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Bevacizumab, Drug: CPT-11 (Irinotecan), Drug: 5-FU Bolus, Drug: 5-FU Infusion, Drug: l-LV (dl-LV) | Arm Label: XELIRI +/- Bevacizumab; Type: EXPERIMENTAL; Interventions: Biological: bevacizumab, Drug: CPT-11 (Irinotecan), Drug: Capecitabine | Intervention Type: BIOLOGICAL; Name: Bevacizumab; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Bolus; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: 5-FU Infusion; Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: DRUG; Name: l-LV (dl-LV); Assigned to Arm(s): FOLFIRI +/- Bevacizumab | Intervention Type: BIOLOGICAL; Name: bevacizumab; Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: CPT-11 (Irinotecan); Assigned to Arm(s): XELIRI +/- Bevacizumab | Intervention Type: DRUG; Name: Capecitabine; Assigned to Arm(s): XELIRI +/- Bevacizumab
B: Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: leucovorin calcium; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: conventional surgery; Assigned to Arm(s): N/A | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): N/A
C: Arm Label: Arm 1: 5-FU + RT; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluorouracil, Radiation: radiation therapy | Arm Label: Arm 2: 5-FU + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: fluorouracil, Drug: oxaliplatin, Radiation: radiation therapy | Arm Label: Arm 3: Capecitabine + RT; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Radiation: radiation therapy | Arm Label: Arm 4: Capecitabine + RT + Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: capecitabine, Drug: oxaliplatin, Radiation: radiation therapy | Intervention Type: DRUG; Name: capecitabine; Assigned to Arm(s): Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: DRUG; Name: fluorouracil; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin | Intervention Type: DRUG; Name: oxaliplatin; Assigned to Arm(s): Arm 2: 5-FU + RT + Oxaliplatin, Arm 4: Capecitabine + RT + Oxaliplatin | Intervention Type: RADIATION; Name: radiation therapy; Assigned to Arm(s): Arm 1: 5-FU + RT, Arm 2: 5-FU + RT + Oxaliplatin, Arm 3: Capecitabine + RT, Arm 4: Capecitabine + RT + Oxaliplatin
D: Arm Label: S-1 and Oxaliplatin; Type: EXPERIMENTAL; Interventions: Drug: S-1 & Oxaliplatin | Arm Label: Capecitabine and Oxaliplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Capecitabine & Oxaliplatin | Intervention Type: DRUG; Name: S-1 & Oxaliplatin; Assigned to Arm(s): S-1 and Oxaliplatin | Intervention Type: DRUG; Name: Capecitabine & Oxaliplatin; Assigned to Arm(s): Capecitabine and Oxaliplatin

Answer: A